The efficacy of treatments with tumor necrosis factor (TNF) and IL-1 inhibitors strongly support the key role of inflammatory cytokines in the pathogenesis of RA [9,10] and points to therapeutic approaches directed toward regulation of cytokine networks involved in RA. Here, IL1B is linked to rheumatoid arthritis.